Egyptian International Pharmaceutical Investments (CAI:PHAR) Total Stockholders Equity : E£4,257 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Total Stockholders Equity?

Egyptian International Pharmaceutical Investments's Total Stockholders Equity for the quarter that ended in Dec. 2023 was E£4,257 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Egyptian International Pharmaceutical Investments's Book Value per Share for the quarter that ended in Dec. 2023 was E£28.62. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Egyptian International Pharmaceutical Investments's Debt-to-Equity for the quarter that ended in Dec. 2023 was 1.15.

Egyptian International Pharmaceutical Investments Total Stockholders Equity Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Total Stockholders Equity Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

2,949.84

2,843.94

2,970.65

3,239.33

4,257.41

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															3,239.33	3,391.98	3,449.63	4,078.20	4,257.41

Egyptian International Pharmaceutical Investments (CAI:PHAR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Egyptian International Pharmaceutical Investments's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4257.408	-	0)	/	148.756
	=	28.62

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Egyptian International Pharmaceutical Investments's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2047.522	+	2832.452)	/	4257.408
	=	1.15

Egyptian International Pharmaceutical Investments Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.